Educating Providers for Outpatient CAR T Administration

EP: 1.Overview of CAR T-cell Therapy in R/R NHL

EP: 2.Transplant-Eligibility and CAR T Considerations in R/R NHL

EP: 3.ZUMA-1 Trial Using CAR T in R/R NHL

EP: 4.Optimizing CAR T in R/R NHL

EP: 5.Emerging Therapies and Future of CAR T-Cell Therapy

EP: 6.Patient Selection of CAR T-Cell Therapy in R/R NHL

EP: 7.Barriers to CAR T Therapy for R/R NHL

EP: 8.Value of Outpatient CAR T Administration in R/R NHL

EP: 9.Requirements for CAR T in a Community Setting

EP: 10.Outpatient CAR T in R/R NHL: Policies and Procedures

EP: 11.Role of CAR T Administration in the Community

Now Viewing

EP: 12.Educating Providers for Outpatient CAR T Administration

EP: 13.Importance of Monitoring Patient AEs With Outpatient CAR T

EP: 14.Management of Outpatient CAR T Adverse Events

EP: 15.Evolving Treatment Paradigm of R/R NHL and Outpatient CAR T

EP: 16.Future of Outpatient CAR T Administration

Jeff Sharman, MD, provides insight on provider engagement in terms of outpatient CAR T education and thoughts on partnering with CAR T manufacturers in this setting.

Transcript

Jeff Sharman, MD: Within my own program, the start-up training to get engaged in CAR [chimeric antigen receptor] T therapy was quite extensive. We carved out a subdivision of our medical oncology program for those individual providers who were interested in taking on this additional layer of complexity in their practice. Each team and every member was educated regarding management of adverse effects, patient selection, prognostication, and so forth. Beyond that, we also undertook efforts and provided education to the multidisciplinary providers who will be seeing these patients in the hospital when those patients are hospitalized for adverse effects. That included ER [emergency department] pulmonary critical care, cardiology, and neurology. There’s a familiarity that is cross-disciplinary for the eventual certainty that some of these patients will be admitted and will require the assistance of those additional physicians.

In addition to those providers, there were efforts to educate nursing. In our own hospital, these patients would be triaged to the oncology ward where those nurses have received training. In addition, we have what’s called a rapid-response team, and that rapid-response team triages patients who are having acute deteriorations in their clinical care. Those providers are always instantly available to a deteriorating patient. It’s not only the physicians but also the associated nursing staff who have been educated.

There are 2 aspects in which partnering with the manufacturers during the rollout of these therapies is going to be most important. The first is going to be about payers. As we approach the payers in our own marketplace who are already, these payers are understandably going to be having a high level of scrutiny with novel therapeutics that are associated with the price tag that many of these cellular therapies are. There’s going to be a high level of scrutiny and partnering with the manufacturer regarding payer education, and that support in negotiation is going to be essential. And on the medical side as well, having access to those medical monitors or the medical science team from the manufacturer who can support during some of the early experience with CAR T, making sure we’re troubleshooting any management algorithms that we have and having that familiarity and access for questions will be helpful.